Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination

Vaccine

Volumn 29, Issue 40, 2011, Pages 6894-6902

  Lan, Jiaming ^a   Gao, Zhiyun ^a   Xiong, Huabao ^b   Chuai, Xia ^a   Jin, Yuhuai ^a   Li, Jian ^a   Xian, Xian ^a   Liu, Guixia ^a   Xie, Lixin ^a   Zhang, Yonghong ^a   Wang, Yongxiang ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Coxsackievirus B3; DNA; Mice; Prime boost; Protein; Vaccination

Indexed keywords

DNA VACCINE; PRIMER DNA; PROTEIN VP1; UNCLASSIFIED DRUG; VIRUS VACCINE; VP1 PROTEIN VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS B3; COXSACKIE VIRUS B3 INFECTION; COXSACKIE VIRUS INFECTION; DISEASE SEVERITY; DNA IMMUNIZATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; MALE; MOUSE; MUSCLE NECROSIS; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; VIRUS LOAD;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; CELL LINE, TUMOR; COXSACKIEVIRUS INFECTIONS; DNA; ENTEROVIRUS B, HUMAN; HELA CELLS; HUMANS; IMMUNE SERA; IMMUNIZATION; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; LYMPHOCYTES; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; MYOCARDIUM; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC; VIRAL LOAD;

EID: 80052313461     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.049     Document Type: Article

References (44)

1. Kandolf R., Hofschneider P.H. Viral heart disease. Springer Semin Immunopathol 1989, 11(1):1-13.
2. Kawai C. From myocarditis to cardiomyopathy: mechanism of inflammation and cell death. Learning from the past for the future. Circulation 1999, 99(8):1091-1100.
3. Maisch B., Ristic A.D., Hufnagel G., Pankuweit S. Pathophysiology of viral myocarditis: the role of the humoral immune response. Cardiovasc Pathol 2002, 11(2):112-122.
4. See D.M., Tilles J.G. Efficacy of a polyvalent inactivated-virus vaccine in protecting mice from infection with clinical strains of group B coxsackieviruses. Scand J Infect 1994, 26(2):739-747.
5. Godney E.K., Arizpe H.M., Gaunti C.J. Characterization of the antibody response in vaccinated mice protected against coxsackievirus B3-induced myocarditis. Viral Immunol 1987/1988, 1(4):305-314.
6. Werner S., Klump W.M., Schonke H., Hofschneider P.H., Kandolf R. Expression of coxsackievirus B3 capsid proteins in Escherichia coli and generation of virus-specific antisera. DNA 1988, 7(5):307-316.
7. Huber S., Polgar J., Moraska A., Cunningham M., Schwimmbeck P., Schultheiss P. T lymphocyte responses in CVB3-induced murine myocarditis. Scand J Infect Dis Suppl 1993, 88:67-78.
8. Henke A., Wagner E., Whitton J.L., Zell R., Stelzner A. Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization. J Virol 1998, 72(10):8327-8331.
9. Zhang H., Morgan-Capner P., Latif N., Pandolfino Y.A., Fan W., Dunn M.J., et al. Coxsackievirus B3-induced myocarditis, characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain. Am J Pathol 1997, 150(6):2197-2207.
10. Hunziker I.P., Harkins S., Feuer R., Cornell C.T., Whitton J.L. Generation and analysis of an RNA vaccine that protects against coxsackievirus B3 challenge. Virology 2004, 330(1):196-208.
11. Xu W., Shen Y., Jiang Z., Wang Y., Chu Y., Xiong S. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine 2004, 22(27-28):3603-3612.
12. Fairweather D., Rose N.R. Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Method 2007, 41(1):118-122.
13. Li W., Lan J.M., Li J., Jin Y.H., Gao Z.Y., Chuai X., et al. Expression of CVB3 VP1 protein in prokaryotic system and study on its immune effect. Zhong Guo Mian Yi Xue Za Zhi 2009, 25(4):291-298.
14. Bouzari S., Dashti A., Jafari A., Oloomi M. Immune response against adhesins of enteroaggregative Escherichia coli immunized by three different vaccination strategies (DNA/DNA, protein/protein, and DNA/protein) in mice. Comp Immunol Microbiol Infect Dis 2010, 33(3):215-225.
15. Matic S., Minafra A., Boscia D., da Cunha A.T., Martelli G.P. Production of antibodies to little cherry virus 1 coat protein by DNA prime and protein boost immunization. J Virol Methods 2009, 155(1):72-76.
16. Li P., Cao R.B., Zheng Q.S., Liu J.J., Li Y., Wang E.X., et al. Enhancement of humoral and cellular immunity in mice against Japanese encephalitis virus using a DNA prime-protein boost vaccine strategy. Vet J 2010, 183(2):210-216.
17. Pal R., Kalyanaraman V.S., Nair B.C., Whitney S., Keen T., Hocker L. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 2006, 348(2):341-353.
18. Liang R., van den Hurk J.V., Zheng C., Yu H., Pontarollo R.A., Babiuk L.A., et al. Immunization with plasmid DNA encoding a truncated, secreted form of the bovine viral diarrhea virus E2 protein elicits strong humoral and cellular immune responses. Vaccine 2005, 23(45):5252-5262.
19. Martin J.E., Sullivan N.J., Enama M.E., Gordon I.J., Roederer M., Koup R.A., et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006, 13(11):1267-1277.
20. Alekseeva E., Sominskaya I., Skrastina D., Egorova I., Starodubova E., Kushners E., et al. Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen. Genet Vaccines Ther 2009, 7:7.
21. Henke A., Huber S., Stelzner A., Whitton J.L. The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J Virol 1995, 69:6720-6728.
22. Haarmann C.M., Schwimmbeck P.L., Mertens T., Schultheiss H.P., Strauer B.E. Identification of serotype-specific and nonserotype-specific B-cell epitopes of coxsackie B virus using synthetic peptides. Virology 1994, 200(2):381-389.
23. Michable A., Lindberg P., Stalhandske K., Petterson U. Genome of coxsackievirus B3. Virology 1987, 156(1):50-63.
24. Muckelbauer J.K., Kremer M., Minor I., Diana G., Dutko F.J., Groarke J., et al. The structure of coxsackievirus B3 at 3.5A resolution. Structure 1995, 3(7):653-667.
25. Kim J.Y., Jeon E.S., Lim B.K., Kim S.M., Chung S.K., Kim J.M., et al. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge. Vaccine 2005, 23(14):1672-1679.
26. Wang L.S., Liu J.X., Zhu L., Lu D.Y. Study on the humoral and cellular immune responses in the mice induced with DNA vaccines of CVB3 structural and nonstructural protein. Chin J Microbiol Immunol 2001, 21(1):46-49.
27. Roufika S., Paquina P., Britten M. Use of high-performance size exclusion chromatography to characterize protein aggregation in commercial whey protein concentrates. Int Dairy J 2005, 15(3):231-241.
28. Rezkalla S., Kloner R.A., Khatib G., Smith F.E., Khatib R. Effect of metoprolol in acute coxsackievirus B3 murine myocarditis. J Am Coll Cardiol 1988, 12(2):412-414.
29. Feldman A.M., McNamara D., Myocarditis Engl J Med 2000, 343(19):1388-1398.
30. Ramshaw I.A., Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000, 21(4):163-165.
31. Dunachie S.J., Hill A.V. Prime-boost strategies for malaria vaccine development. J Exp Biol 2003, 206(Pt 21):3771-3779.
32. Vaine M., Wang S., Hackett A., Arthos J., Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 2010, 28(17):2999-3007.
33. Lu S. Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol 2006, 28(3):255-265.
34. Li Y.H., Huang S., Du M., Bian Z., Chen Z., Fan M.W. Immunogenic characterization and protection against Streptococcus mutans infection induced by intranasal DNA prime-protein boost immunization. Vaccine 2010, 28(32):5370-5376.
35. Law M., Cardoso R.M., Wilson I.A., Burton D.R. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J Virol 2007, 81(8):4272-4285.
36. Davtyan H., Mkrtichyan M., Movsesyan N., Petrushina I., Mamikonyan G., Cribbs D.H., et al. DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther 2010, 17(2):261-271.
37. Parish C.R. The relationship between humoral and cell-mediated immunity. Transplant Rev 1972, 13(1):35-66.
38. Sher A., Coffman R.L. Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annu Rev Immunol 1992, 10:385-409.
39. Letvin N.L., Montefiori D.C., Yasutomi Y., Perry H.C., Davies M.E., Lekutis C., et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci USA 1997, 94(17):9378-9383.
40. Excler J.L., Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS 1997, 11(Suppl. A):S127-S137.
41. Kim J.Y., Jeon E.S., Lim B.K., Kim S.M., Chung S.K., Kim J.M., et al. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice protective effects of capsid proteins against viral challenge. Vaccine 2005, 23(14):1672-1679.
42. Sauter P., Hober D. Mechanisms and results of the antibody-dependent enhancement of viral infections and role in the pathogenesis of coxsackievirus B-induced diseases. Microbes Infect 2009, 11(4):443-451.
43. O'Hagan D.T., Singh M., Ulmer J.B. Microparticle-based technologies for vaccines. Methods 2006, 40(1):10-19.
44. Ho J., Huang Y., Danquah M.K., Wang H., Forde G.M. Synthesis of biodegradable polymer-mesoporous silica composite microspheres for DNA prime-protein boost vaccination. Eur J Pharm Sci 2010, 39(5):412-420.